Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats

Reproductive Toxicology

Volumn 20, Issue 1, 2005, Pages 165-173

  Chung, Moon Koo ^a   Kim, Jong Choon ^b   Han, Sang Seop ^a  

^a Korea Institute of Toxicology   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Anticancer agent; Camptothecin; CKD 602; Rats; Teratogenicity

Indexed keywords

7 [2 (N ISOPROPYLAMINO)ETHYL]CAMPTOTHECIN; ANTINEOPLASTIC AGENT; BELOTECAN; CAMPTOTHECIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOPHTHALMIA; ARTICLE; BODY WEIGHT; BONE MALFORMATION; BRAIN VENTRICLE DILATATION; BRAIN WEIGHT; CESAREAN SECTION; CONTROLLED STUDY; EMBRYO RESORPTION; EMBRYOTOXICITY; FEMALE; FETUS DEATH; FETUS WEIGHT; FOOD INTAKE; GESTATIONAL AGE; LITTER SIZE; MALE; MATING; METATARSAL BONE; NONHUMAN; OSSIFICATION; PLACENTA WEIGHT; RAT; RIB MALFORMATION; SACRUM; SKELETON MALFORMATION; SPERM; SPLEEN WEIGHT; STERNUM; THORAX DEFORMITY; VAGINAL LAVAGE; VERTEBRA MALFORMATION;

EID: 16244407166     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2005.01.004     Document Type: Article

References (35)

1. J.A. Gottlieb, A.M. Guarino, J.B. Call, V.T. Oliverio, and J.B. Block Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880) Cancer Chemother Rep 54 1970 461 470
2. F.M. Muggia, P.J. Creven, H.H. Hansen, M.H. Cohen, and O.S. Selawry Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880) Cancer Chemother Rep 56 1972 515 521
3. C.G. Moertel, A.J. Schutt, R.J. Reitmeier, and R.G. Hahn Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer Cancer Chemother Rep 56 1972 95 101
4. H. Bleiberg, and M.L. Rothenberg CPT-11: from DNA topology to clinical activity Semin Oncol 23 1996 1 50
5. C. Kolimannsberger, K. Mross, A. Jakob, L. Kanz, and C. Bokemyer Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience Oncology 56 1999 1 12
6. W. Dahut, N. Harolod, C. Takimototo, C. Allegra, A. Chen, and J.M. Hamilton Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients J Clin Oncol 14 1996 1236 1244
7. L. Iyer, and M.J. Ratain Clinical pharmacology of camptothecins Cancer Chemother Pharmacol 42 1998 S31 S43
8. C.H. Takimoto, J. Wright, and S.G. Arbuck Clinical applications of the camptothecins Biochim Biophys Acta 1400 1998 107 119
9. J. Fassberg, and V.J. Stella A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues J Pharm Sci 81 1992 676 684
10. R.P. Hertzberg, M.J. Caranfa, K.G. Holden, D.R. Jakas, G. Gallagher, and M.R. Mattern Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity J Med Chem 32 1989 715 720
11. H. Hashimoto, S. Chatterjee, and N.A. Berger Mutagenic activity of topoisomerase I inhibitors Clin Cancer Res 1 1995 369 376
12. J. O'Leary, and F.M. Muggia Camptothecins: a review of their development and schedules of administration Eur J Cancer 34 1998 1500 1508
13. J.H. Lee, J.M. Lee, J.K. Kim, S.K. Ahn, S.J. Lee, and M.Y. Kim Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor Arch Pharm Res 21 1998 581 590
14. J.H. Kim, S.K. Lee, J.L. Lim, H.J. Shin, and C.I. Hong Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics Int J Pharm 239 2002 207 211
15. J.H. Lee, J.M. Lee, K.H. Lim, J.K. Kim, S.K. Ahn, and Y.J. Bang Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative Ann NY Acad Sci 922 2000 324 325
16. E.J. Kim, R.K. Lee, J.E. Suh, S.S. Han, and J.K. Kim Safety pharmacology of CKD-602, a novel anticancer agent Arzneimittel Forschung 53 2003 272 279
17. K.W. Ha, H.Y. Oh, O.S. Heo, C.H. Park, S.J. Sohn, and E.S. Han Genotoxicity studies of an anticancer agent of camptothecin series, CKD-602 Environ Mutag Carcinog 18 1998 129 134
18. M. Itabashi, T. Inoue, and T. Fujii Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rats Clin Rep 24 1990 125 129
19. M. Itabashi, K. Yoshida, and K. Suzyuki Reproduction and developmental studies of CPT-11: study on administration of the test substance during the period of organogenesis in rabbits Clin Rep 24 1990 157 161
20. A.B. Dawson A note on the staining of the skeleton of cleared specimens with Alizarin Red S Stain Technol 1 1926 123 124
21. J.G. Wilson Methods for administering agents and detecting malformations in experimental animals in teratology J.G. Wilson Principles and techniques 1965 University of Chicago Press Chicago 262 277
22. K. Nishimura A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses Cong Anom 14 1974 23 40
23. L.D. Wise, S.L. Beck, D. Beltrame, B.K. Beyer, I. Chahoud, and R. Clark Terminology of developmental abnormalities in common laboratory animals (Version 1) Teratology 55 1997 249 292
24. H. Morita, F. Ariyuki, N. Inomata, K. Nishimura, Y. Kasegawa, and M. Miyamoto Spontaneous malformations in laboratory animals: frequency of external, internal and skeletal malformations in rats, rabbits and mice Cong Anom 27 1987 147 206
25. J.C. Kim, S.J. Lee, J.S. Bae, J.I. Park, Y.B. Kim, and M.K. Chung Historical control data for developmental toxicity study in Sprague-Dawley rats J Toxicol Public Health 17 2001 83 90
26. M. Ogawa Novel anticancer drugs in Japan J Cancer Res Clin Oncol 125 1999 134 140
27. N. Takahashi, S. Kai, H. Kohmura, K. Ishikawa, K. Kuroyanagi, and Y. Hamajima Reproduction studies of VP 16-213 (II) - oral administration to rats during the period of fetal organogenesis J Toxicol Sci 11 1986 195 225
28. N. Takahashi, S. Kai, H. Kohmura, K. Ishikawa, K. Kuroyanagi, and Y. Hamajima Reproduction studies of VP 16-213 (III) - oral administration to rabbits during the period of fetal organogenesis J Toxicol Sci 11 1986 227 239
29. T. Nagao, S. Yoshimura, Y. Saito, and K. Imai Developmental toxicity of the topoisomerase inhibitor, etoposide, in rabbits after intravenous administration Teratogen Carcinigen Mutagen 19 1999 233 241
30. S.M. Sieber, J. Whang-Peng, C. Botkin, and T. Knutsen Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16-213 and VM-26) in mice Teratology 18 1978 31 48
31. K.S. Khera Maternal toxicity: a possible etiological factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species Teratology 31 1985 129 153
32. K.S. Khera Maternal toxicity in human and animals: effects on fetal development and criteria for detection Teratogen Carcinogen Mutagen 7 1987 287 295
33. R.J. Kavlock, N. Cernoff, and E.H. Rogers The effect of acute maternal toxicity on fetal development in the mouse Teratogen Carcinogen Mutagen 5 1985 3 13
34. N. Chernoff, E.H. Rogers, and R.J. Kavlock An overview of maternal toxicity and prenatal development: considerations for developmental toxicity hazard assessments Toxicology 59 1989 111 125
35. I. Chahoud, A. Ligensa, L. Dietzel, and A.S. Faqi Correlation between maternal toxicity and embryo/fetal effects Reprod Toxicol 13 1999 375 381